Investigational BAT4406F Performs in Phase 2/3 Study of NMOSD, Leading to Early ...

Retrieved on: 2025-09-04 17:06:19

Tags for this article:

Click the tags to see associated articles and topics

Investigational BAT4406F Performs in Phase 2/3 Study of NMOSD, Leading to Early .... View article details on hiswai:

Excerpt

Bio-Thera Solutions announced that its pivotal trial of BAT4406F, an anti-CD20 monoclonal antibody, for neuromyelitis optica spectrum disorder ...

Article found on: www.neurologylive.com